The CSC research space is proving to be challenging and fraught with controversy.!--h2>
The focus of this GEN Market & Tech Analysis report is to frame the challenging space of cancer stem cells (CSCs). Highlights of this report:
The potential relationship between circulating tumor cells (CTCs) and CSCs is unclear at present—this is important since it underlines the mechanism[s] by which components of the primary tumor migrate to distal sites and induce mets, the drivers for morbidity and mortality in late-stage cancer patients.
We have performed market surveys of researchers studying CSCs as a means to understand the surface markers deployed (to characterize CSCs) as well as the intracellular signal transduction pathways being studied in the context of CSCs.
Also presented in this report are the various associations of markers with distinct cancer classes documented thusfar—it appears that distinct classes of CSCs with different surface phenotypes may be associated with different classes of cancer and would suggest that the CSC pool is distinct in different cancer classes ("one size does not fit all").
This space is an area of continuing industry coverage for us, and in future reports we'll document advances in the CSC space as they occur as well as an update on the clinical trials underway in this field.
Enal Razvi, Ph.D., conducted his doctoral work on viral immunology and subsequent to receiving his Ph.D. went on to the Rockefeller University in New York to serve as Aaron Diamond Post-doctoral fellow under Professor Ralph Steinman [Nobel Prize Winner in 2011 for his discovery of dendritic cells in the early-70s with Zanvil Cohn]. Subsequently, Dr. Razvi completed his research fellowship at Harvard Medical School. For the last two decades Dr. Razvi has worked with small and large companies and consulted for more than 100 clients worldwide. He currently serves as Biotechnology Analyst and Managing Director of SelectBio U.S. He can be reached at [email protected].